PEAR.Q Stock Overview
A commercial-stage healthcare company, develops and sells software-based medicines in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pear Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.02 |
| 52 Week Low | US$0.000001 |
| Beta | 8.21 |
| 1 Month Change | 0% |
| 3 Month Change | -99.00% |
| 1 Year Change | -99.97% |
| 3 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch
Apr 17
Recent updates
Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch
Apr 17Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue
Aug 18Pear Therapeutics providing Core Behavioral with opioid use disorder digital therapeutic
Aug 03Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction
May 21Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets
Apr 04Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy
Jan 10Shareholder Returns
| PEAR.Q | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 0% | 2.0% | 3.1% |
| 1Y | -100.0% | -5.1% | 23.7% |
Return vs Industry: PEAR.Q underperformed the US Healthcare Services industry which returned -3.2% over the past year.
Return vs Market: PEAR.Q underperformed the US Market which returned 25.6% over the past year.
Price Volatility
| PEAR.Q volatility | |
|---|---|
| PEAR.Q Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 9.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PEAR.Q's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine PEAR.Q's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 200 | n/a | peartherapeutics.com |
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines in the United States. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastroenterology, cardiology, and oncology.
Pear Therapeutics, Inc. Fundamentals Summary
| PEAR.Q fundamental statistics | |
|---|---|
| Market cap | US$142.00 |
| Earnings (TTM) | -US$75.49m |
| Revenue (TTM) | US$12.69m |
0.0x
P/S Ratio0.0x
P/E RatioIs PEAR.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEAR.Q income statement (TTM) | |
|---|---|
| Revenue | US$12.69m |
| Cost of Revenue | US$7.39m |
| Gross Profit | US$5.30m |
| Other Expenses | US$80.79m |
| Earnings | -US$75.49m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 41.75% |
| Net Profit Margin | -594.70% |
| Debt/Equity Ratio | 89.7% |
How did PEAR.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/27 04:06 |
| End of Day Share Price | 2024/05/27 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pear Therapeutics, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Cherny | BofA Global Research |
| Michael Gorman | BTIG |
| Marie Thibault | BTIG |